Business
Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Valneva Reports First Quarter 2026 Financial Results and Provides Corporate
About this update from Valneva Se
Total product sales of €30.5 million Cash position of €105.3 million as of end March 2026, excluding proceeds from successful reserved offering completed in April 20261Program launched in April to further reduce operating expensesPfizer expected to file regulatory submissions for Lyme disease vaccine candidateLyon (France), May 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ended March 31, 2026, provided key corporate updates, and updated its 2026 financial guidance. The condensed consolidated interim financial results are available on the Company’s website (Financial Reports – Valneva). Valneva will provide a live webcast of its first quarter 2026 results conference call beginning at 3 p.m. CEST/9 a.m. EDT today. This webcast will also be available on the Company’s website. Please refer to this link: https://edge.media-server.com/mmc/p/xbkzgkz7First quarter 2026 Financial UpdateTotal revenues were €30.9 million, including €30.5 million in product sales, compared with €49.2 million and €48.6 million, respectively, in the first quarter of 2025, mainly reflecting the planned wind-down of third-party sales (-97.6% versus the first quarter of 2025) and a different shipment phasing to the U.S. Department of DefenseOperating cash burn continued to decline, improving to €0.3 million in the first quarter of 2026, compared to €8.1 million in the first quarter of 2025Cash position of €105.3 million as of March 31, 2026, compared to €109.7 million as of December 31, 2025 Excludes €37.0 million in gross proceeds from recent successful reserved offering1Net loss of €32.1 million, compared with a net loss of €9.2 million in the first quarter of 2025 mainly impacted by one-off effects in cost of goods (termination of contracts, standard cost adjustment, inventory write-offs), in addition to idle cost and lower sales.Financial Outlook Valneva is adjusting its 2026 sales and revenue guidance partially as a result of an emerging adverse trend in travel vaccine uptake across key markets, driven by geopolitical factors. The Company is therefore revising its product sales guidance to €135 million to €150 million from €145 million to €160 million previously Other revenues are reconfirmed – resulting in a new total revenue guidance of €145 million to €160 millionAs part of t...